LXRX vs. IRWD, EBS, CDXS, RIGL, XOMA, VNDA, VSTM, SGMO, ACHV, and RGLS
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Ironwood Pharmaceuticals (IRWD), Emergent BioSolutions (EBS), Codexis (CDXS), Rigel Pharmaceuticals (RIGL), XOMA (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Sangamo Therapeutics (SGMO), Achieve Life Sciences (ACHV), and Regulus Therapeutics (RGLS). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals vs.
Ironwood Pharmaceuticals (NASDAQ:IRWD) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.
Ironwood Pharmaceuticals has a net margin of -0.65% compared to Lexicon Pharmaceuticals' net margin of -4,109.41%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Lexicon Pharmaceuticals' return on equity.
Lexicon Pharmaceuticals has lower revenue, but higher earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Ironwood Pharmaceuticals received 30 more outperform votes than Lexicon Pharmaceuticals when rated by MarketBeat users. However, 64.69% of users gave Lexicon Pharmaceuticals an outperform vote while only 61.08% of users gave Ironwood Pharmaceuticals an outperform vote.
Ironwood Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500.
In the previous week, Ironwood Pharmaceuticals had 5 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Ironwood Pharmaceuticals and 0 mentions for Lexicon Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.58 beat Lexicon Pharmaceuticals' score of -0.63 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 12.9% of Ironwood Pharmaceuticals shares are owned by insiders. Comparatively, 4.5% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Ironwood Pharmaceuticals presently has a consensus price target of $10.40, indicating a potential upside of 184.15%. Lexicon Pharmaceuticals has a consensus price target of $6.00, indicating a potential upside of 769.57%. Given Lexicon Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Ironwood Pharmaceuticals.
Summary
Ironwood Pharmaceuticals beats Lexicon Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LXRX) was last updated on 1/21/2025 by MarketBeat.com Staff
